https://www.live-feeds.com/feed/success-after-a-century-of-failures-inside-moderna-and-merck-s-cancer-vaccine-breakthroughContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/success-after-a-century-of-failures-inside-moderna-and-merck-s-cancer-vaccine-breakthroughhttps://www.live-feeds.com/feed/success-after-a-century-of-failures-inside-moderna-and-merck-s-cancer-vaccine-breakthrough#u52553Mon, 31 Aug 2026 00:41:07 +0000Moderna and Merck's cancer vaccine, V940, has shown promise in a late-stage trial, with results indicating it may keep melanoma from coming back. The vaccine, which uses mRNA technology, was tested in patients with stage III or IV melanoma. The trial's positive outcome has generated hype, but some experts caution that the data is not yet fully understood.Why it mattersThe development of a cancer vaccine has been a long-sought goal in the medical community, with many failures over the past century. Moderna and Merck's collaboration on V940 marks a significant milestone in the fig